Company intelligence / Profile preview
Arno Therapeutics, Inc.
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
Overview
Arno Therapeutics was a clinical-stage biopharmaceutical company focused on developing oncology therapeutics. Its lead program, onapristone—a type I anti-progestin—was evaluated in Phase I/II trials for breast, endometrial, and prostate cancers. Other pipeline assets included AR‑42 (a deacetylase inhibitor) and AR‑12 (an oral agent for solid tumors and hematological malignancies). The company ceased operations in late 2017 after selling its remaining assets due to lackluster clinical data and financial constraints[6].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesHormone blockersDeacetylase inhibitors
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Arno Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arno Therapeutics, Inc..